Aptose Announces Planned Departure of Chief Business Officer

Aptose Biosciences (NASDAQ:APTO, TSX:APS) announced its senior vice president and chief business officer Avanish Vellanki will leave the company and its board of directors.
As quoted in the press release:

The resignation is effective immediately, and the Board of Directors does not contemplate replacing Mr. Vellanki at this time. Aptose is focused on the development of CG’806, an oral preclinical compound being developed for patients with FLT3-driven acute myeloid leukemia (AML) and certain BTK-driven B-cell malignancies.

“On behalf of everyone at Aptose, we thank Avanish for his contributions during his time with the Company. He remains a friend of the Company and we wish the best for him in his future endeavors,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

“It was a pleasure to be part of the team over the past three years,” said Mr. Vellanki. “I remain very excited about the prospects for the Aptose pipeline.”

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

Click here to read the full press release.